Marketing-authorisation holder
Hoffmann-La Roche Limited
195 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder
195 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 195
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| ACTEMRA162 mg / 0.9 ml · Solution | Tocilizumab | Canada | Marketed | 2019 |
| ACTEMRA200 mg / 10 ml · Solution | Tocilizumab | Canada | Marketed | 2010 |
| ACTEMRA162 mg / 0.9 ml · Solution | Tocilizumab | Canada | Marketed | 2014 |
| ACTEMRA80 mg / 4 ml · Solution | Tocilizumab | Canada | Marketed | 2010 |
| ACTEMRA400 mg / 20 ml · Solution | Tocilizumab | Canada | Marketed | 2010 |
| ACTIVASE RT-PA100 mg / kit + 100 ml / kit · Liquid, Powder For Solution | Alteplase, Water | Canada | Marketed | 1996 |
| ACTIVASE RT-PA50 mg / kit + 50 ml / kit · Liquid, Powder For Solution | Alteplase, Water | Canada | Marketed | 1998 |
| ALECENSARO150 mg · Capsule | Alectinib | Canada | Marketed | 2016 |
| AVASTIN25 mg / ml · Solution | Bevacizumab | Canada | Marketed | 2005 |
| CATHFLO2 mg / vial · Powder For Solution | Alteplase | Canada | Marketed | 2002 |
| CELLCEPT500 mg · Tablet | Mycophenolate mofetil | Canada | Marketed | 1998 |
| CELLCEPT200 mg / ml · Powder For Suspension | Mycophenolate mofetil | Canada | Marketed | 2002 |
| CELLCEPT250 mg · Capsule | Mycophenolate mofetil | Canada | Marketed | 1995 |
| CELLCEPT I.V.500 mg / vial · Powder For Solution | Mycophenolate mofetil | Canada | Marketed | 1999 |
| COLUMVI10 mg / 10 ml · Solution | Glofitamab | Canada | Marketed | 2023 |
| COLUMVI2.5 mg / 2.5 ml · Solution | Glofitamab | Canada | Marketed | 2023 |
| COTELLIC20 mg · Tablet | Cobimetinib | Canada | Marketed | 2016 |
| ENSPRYNG120 mg / ml · Solution | Satralizumab | Canada | Marketed | 2020 |
| ERIVEDGE150 mg · Capsule | Vismodegib | Canada | Marketed | 2013 |
| ESBRIET801 mg · Tablet | Pirfenidone | Canada | Marketed | 2017 |
| ESBRIET267 mg · Tablet | Pirfenidone | Canada | Marketed | 2017 |
| EVRYSDI5 mg · Tablet | Risdiplam | Canada | Marketed | 2025 |
| EVRYSDI0.75 mg / ml · Powder For Solution | Risdiplam | Canada | Marketed | 2021 |
| GAZYVA25 mg / ml · Solution | Obinutuzumab | Canada | Marketed | 2014 |
| HEMLIBRA150 mg / ml · Solution | Emicizumab | Canada | Marketed | 2018 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| Canada | 195 | 72 | 123 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Health Canada, Drug Product Database, company API, entire response observed 2026-10-10T15:12:05.508784+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.
Licence: Open Government Licence Canada
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.